182 related articles for article (PubMed ID: 873663)
1. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
[TBL] [Abstract][Full Text] [Related]
2. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
Bartle WR; Coates PE; Fisher MM; Louman FJ
Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone. II. Bioavailability.
Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
[TBL] [Abstract][Full Text] [Related]
4. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
Krause W; Karras J; Jakobs U
J Chromatogr; 1983 Oct; 277():191-9. PubMed ID: 6643605
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.
Tidd MJ; Collins WT; Chamberlain J
J Int Med Res; 1976; 4(2):86-95. PubMed ID: 1037443
[TBL] [Abstract][Full Text] [Related]
6. Enhancement by food of canrenone bioavailability from spironolactone.
Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
[TBL] [Abstract][Full Text] [Related]
7. Application of a simple fluorometric method on absorption of canrenone.
Radó JP; Szende L; Takó J; Nagy O; Kozma C
Int J Clin Pharmacol Biopharm; 1976 Mar; 13(2):123-6. PubMed ID: 1254376
[TBL] [Abstract][Full Text] [Related]
8. [Bioavailability studies of two spironolactone-preparations (author's transl)].
Vergin H; Nuss U; Schwarzländer F; Strobel K; Weigand W; Hitzenberger G
Arzneimittelforschung; 1981; 31(9):1498-503. PubMed ID: 7197963
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing comparative bioavailability of spironolactone tablets.
Clarke JM; Ramsay LE; Shelton JR; Tidd MJ; Murray S; Palmer RF
J Pharm Sci; 1977 Oct; 66(10):1429-32. PubMed ID: 579186
[TBL] [Abstract][Full Text] [Related]
10. [Biological availability of spironolactone in two different galenic forms (author's transl)].
Rameis H; Hitzenberger G; Horwatitsch H
Dtsch Med Wochenschr; 1979 Jun; 104(24):881-3. PubMed ID: 446311
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
Vergin H; Nuss U; Strobel K
Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
[TBL] [Abstract][Full Text] [Related]
12. [Studies of biological availability. A critical assessment based on a study of spironolactone preparations].
Rameis H; Bacher S
Wien Med Wochenschr; 1988 Apr; 138(6-7):156-60. PubMed ID: 3394332
[TBL] [Abstract][Full Text] [Related]
13. The bioavailability of spironolactone hydrochlorothiazide combination preparation.
Rameis H; Hitzenberger G; Horwatitsch H
Int J Clin Pharmacol Ther Toxicol; 1982 Jul; 20(7):327-33. PubMed ID: 7107086
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples.
Sandall JM; Millership JS; Collier PS; McElnay JC
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jul; 839(1-2):36-44. PubMed ID: 16510319
[TBL] [Abstract][Full Text] [Related]
16. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
[TBL] [Abstract][Full Text] [Related]
17. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.
Karim A; Zagarella J; Hutsell TC; Dooley M
Clin Pharmacol Ther; 1976 Feb; 19(2):177-82. PubMed ID: 1261155
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses].
Doignon JL; Grognet JM; Thébault JJ; Caplain M; Capron MH; Pelletier B; Wehrlen M; Istin M
Therapie; 1990; 45(6):475-81. PubMed ID: 2080486
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
[TBL] [Abstract][Full Text] [Related]
20. Species differences in the metabolism and disposition of spironolactone.
Karim A; Kook C; Zitzewitz DJ; Zagarella J; Doherty M; Campion J
Drug Metab Dispos; 1976; 4(6):547-55. PubMed ID: 11976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
